Genovate Biotechnology Co., Ltd. (TPEX:4130)
Taiwan · Delayed Price · Currency is TWD 26.70
0.00 (-0.37%)
Jul 21, 2026, 2:31 PM CST
Genovate Biotechnology Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,651 | 3,151 | 2,324 | 2,909 | 3,506 | 2,675 | |
Market Cap Growth | 70.97% | 35.56% | -20.11% | -17.02% | 31.05% | -15.11% |
Enterprise Value | 2,542 | 2,687 | 1,801 | 2,370 | 3,045 | 2,281 |
Last Close Price | 26.70 | 26.83 | 19.65 | 24.24 | 29.44 | 22.16 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | 269.72 | 90.45 | 99.18 | - | 7191.72 |
Forward PE | - | 38.71 | 38.71 | 38.71 | 38.71 | 38.71 |
PS Ratio | 7.74 | 6.40 | 4.55 | 5.51 | 7.99 | 6.16 |
PB Ratio | 1.83 | 2.28 | 1.60 | 1.98 | 2.49 | 1.94 |
P/TBV Ratio | 1.84 | 2.29 | 1.61 | 1.99 | 2.49 | 1.94 |
P/FCF Ratio | - | - | 95.52 | 51.22 | - | - |
P/OCF Ratio | 2016.14 | 71.96 | 42.18 | 34.32 | 2321.83 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.39 | 5.46 | 3.53 | 4.48 | 6.94 | 5.25 |
EV/EBITDA Ratio | 161.79 | 63.93 | 31.05 | 38.91 | 152.67 | 70.55 |
EV/EBIT Ratio | - | 388.55 | 76.89 | 87.75 | - | - |
EV/FCF Ratio | - | - | 74.03 | 41.72 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00 |
Debt / EBITDA Ratio | 0.09 | 0.04 | 0.04 | 0.01 | 0.09 | 0.02 |
Debt / FCF Ratio | - | - | 0.11 | 0.01 | - | - |
Net Debt / Equity Ratio | -0.56 | -0.35 | -0.36 | -0.37 | -0.35 | -0.28 |
Net Debt / EBITDA Ratio | -65.59 | -11.42 | -8.94 | -8.84 | -24.83 | -12.02 |
Net Debt / FCF Ratio | 30.57 | 40.22 | -21.32 | -9.48 | 22.47 | 11.03 |
Asset Turnover | 0.26 | 0.32 | 0.32 | 0.33 | 0.28 | 0.28 |
Inventory Turnover | 2.28 | 2.18 | 2.23 | 2.23 | 1.99 | 2.04 |
Quick Ratio | 11.25 | 4.54 | 4.48 | 5.34 | 4.71 | 4.38 |
Current Ratio | 12.67 | 5.74 | 5.61 | 6.56 | 5.93 | 5.74 |
Return on Equity (ROE) | -0.54% | 0.83% | 1.76% | 2.04% | -0.88% | 0.03% |
Return on Assets (ROA) | -0.58% | 0.28% | 0.92% | 1.07% | -0.56% | -0.05% |
Return on Invested Capital (ROIC) | -1.93% | 0.66% | 2.08% | 2.79% | -1.46% | -0.01% |
Return on Capital Employed (ROCE) | -0.90% | 0.50% | 1.60% | 1.80% | -1.00% | -0.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -0.25% | 0.37% | 1.11% | 1.01% | -0.35% | 0.01% |
FCF Yield | -0.99% | -0.38% | 1.05% | 1.95% | -0.63% | -1.32% |
Dividend Yield | 0.37% | - | 0.51% | 0.59% | 0.57% | 1.50% |
Payout Ratio | - | 95.46% | 63.84% | 65.25% | - | 11656.45% |
Buyback Yield / Dilution | -2.55% | 0.81% | 0.24% | -1.49% | 0.03% | 0.14% |
Total Shareholder Return | -2.19% | 0.81% | 0.75% | -0.91% | 0.60% | 1.64% |